Safarian will speak on “Global Study Experiences: Lessons from Observing Regional Variations” which is part of the “Clinical Projects: Faster and Smarter? It’s All in the Planning! session.

Date: June 15, 2:00PM – 3:30PM
Session #: 246
Room #: 140B

Novotech is the largest full-service Australian CRO with an extensive operations footprint across Asia, and has helped global customers conduct trials across a population base of more than 1.5 billion people in the Australasian region.

Headquartered in Sydney, Novotech works with biotechnology and pharmaceutical companies in North America and Europe to bring new products to the global market by offering a full range of ICH-compliant clinical services, from first human exposure through to completion of Phase III trials.

“Judging by the growth in number of new clinical trials starting in the region over the last few years, Asia provides a tremendous untapped opportunity to the drug development industry,” said Safarian.

The DIA Annual Meeting is the premier event for professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products. There is no other industry meeting of its kind that can rival the breadth and depth of experience that this meeting delivers. With 25 content-area tracks, 330 sessions and 20 tutorials, presentations are geared to attendees at all disciplines, works settings, and experience levels.

About Novotech
Headquartered in Sydney with a regional hub in Malaysia, Novotech is focused on the Asia Pacific region with operations in nine countries including India and South Korea. Novotech also has worldwide reach through the company’s network of strategic partners. Novotech, described by Frost & Sullivan as the best in its industry class for Australia based CROs, brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area. As the largest independent CRO based in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organizations in the region. Since 2006, Novotech has been recognized as Australia’s leading CRO by Frost & Sullivan in its Asia Pacific Excellence in Healthcare awards. For more information, please visit www.novotech-cro.com.

ABOUT THE DRUG INFORMATION ASSOCIATION (DIA)
DIA is a neutral, global, professional, member-driven association of nearly 18,000 industry, academia, and regulatory professionals involved in the discovery, development, and life cycle management of pharmaceuticals, medical devices, and related products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

Media contact:
Susan Fitzpatrick
DatelineMedia Group
Australian office: +61 2 9006 1614
USA office: +1650 7985238
EMAIL: susan@datelinemedia.com

Sydney-based Novotech Adds Global Services for Medidata Rave Clinical Trial Technology

NEW YORK, N.Y. – June 1, 2010 – Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Australian contract research organization (CRO) Novotech has joined Medidata’s ASPire to Win^® channel partner program. As the largest full-service Australian CRO, and with an extensive operations footprint across Asia, Novotech can now offer sponsors a full range of services around the Medidata Rave^® electronic data capture (EDC) and clinical data management (CDM) solution. Novotech plans to leverage Medidata Rave to streamline the clinical research process for customers conducting Phase I–III trials in nine countries and across a range of therapeutic categories.

Headquartered in Sydney, Novotech works with biotechnology and pharmaceutical companies in North America and Europe to bring new products to the global market by offering a full range of ICH-compliant clinical services, from first human exposure through to completion of Phase III trials. Novotech has helped global customers conduct trials across a population base of more than 1.5 billion people in the Australasian region. As the demand for global clinical outsourcing services continues to grow, Novotech selected Medidata Rave and joined the ASPire to Win program for Medidata’s ability to handle large, complex, global studies and its comprehensive partner enablement program.

“Medidata Rave is a robust system with global capabilities, a clear, intuitive interface and widespread acceptance among our global sites,” said Alek Safarian, CEO, Novotech. “Medidata also offers the technology and support that allows us to improve communication and streamline data collection and management with many of our clients based in North America and Europe, enabling us to drive global reach and close the distance gap.”

Novotech is now pursuing Rave Accredited Plus, the most advanced level in Medidata’s channel partner program. Once at this level, Novotech will be positioned to provide the full range of Rave-related services, including end-user training, study build, reporting, outputs, integrations and migrations.

“We are very excited to add Novotech as the first Australian-based CRO in our ASPire to Win program,” said Graham Bunn, Vice President for Global CRO Partnerships, Medidata Solutions. “Our in-depth experience in helping sponsors and CROs facilitate clinical trials on a global scale makes us a natural partner to support Novotech’s clinical support goals, and we look forward to helping drive their future research initiatives.”

Medidata first announced ASPire to Win in April 2005 as a channel partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include more than 25 partners, ranging from smaller clinical consultancies to large, global CROs.
About Novotech
Headquartered in Sydney with a regional hub in Malaysia, Novotech is focused on the Asia Pacific region with operations in nine countries including India and South Korea. Novotech also has worldwide reach through the company’s network of strategic partners. Novotech, described by Frost & Sullivan as the best in its industry class for Australia based CROs, brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area. As the largest independent CRO based in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organizations in the region. Since 2006, Novotech has been recognized as Australia’s leading CRO by Frost & Sullivan in its Asia Pacific Excellence in Healthcare awards. For more information, please visit www.novotech-cro.com.

About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com) is a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of customers’ clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer^®), investigator benchmarking and budgeting (Medidata Grants Manager^®), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor^®), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave^®). Medidata’s diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.

Contact:
Susan McCarron
Lois Paul & Partners
781.782.5767
Susan_McCarron@lpp.com

For Novotech

Susan Fitzpatrick-Napier  USA: +1 650 798 5238  Australia: +1 61 2 90061614

Susan@DMG-Agency.com

NEW YORK – 15/4/10 – Novotech, a leading Australasian CRO, has engaged Citeline to support its clinical development programs and further improve the rate at which Sponsor clinical studies are planned and carried out.

Citeline, the leader in global pharmaceutical intelligence solutions, today announced Novotech will utilize Citeline’s TrialTrove^® to better define their competitive clinical landscape and SiteTrove^® to assist in identifying and tracking clinical trial sites and investigators on a worldwide basis.

“As the most comprehensive clinical trial tracking service in the marketplace, our investment in TrialTrove^® and SiteTrove^® will bring immense benefit to Novotech and our Sponsors in assessing feasibilities and planning new clinical trials in the region,” said Novotech CEO Alek Safarian .

Novotech, which is headquartered in Australia with a management-hub in Malaysia and offices throughout the region, currently manages trials in 9 Asia Pacific countries, including India, Australia, South Korea and Taiwan.

“Our association with Citeline is in keeping with our history of always striving to bring the best combination of technologies and people available in the marketplace for the benefit of our Sponsors worldwide,” said Safarian.

This partnership adds to Citeline’s already impressive list of clients.  Novotech joins an increasing number of CROs in incorporating TrialTrove^® and SiteTrove® into their business process.

“A lot of costly delays in clinical study programs can be avoided with access to accurate intelligence and by a data led approach to investigator selection,” says Robert Roseberry, Commercial Director for Citeline Asia Pacific.   “TrialTrove^® monitors over 100,000 individual clinical trials worldwide and the SiteTrove^® service currently tracks the trial activities of over 190,000 clinical investigators, meaning we are well placed to provide unrivalled levels of intelligence to our clients in this sector.”

-ENDS-

About Citeline:

With 100% of top 20 pharmaceutical companies and many leading CROs as enterprise wide clients, Citeline is the leading provider of real time, global R&D intelligence to the biopharmaceutical industry.  Citeline tracks clinical trials, drugs in development, clinical investigators and trial sites on a worldwide basis.  Citeline acts as an information partner by delivering enterprise wide access to its information via a suite of Web based tools in combination with direct access to expert therapeutic area analysts who provide research support according to specific client requests.  Citeline is an operating subsidiary of Informa plc (LSE: INF), a leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities.  More information available at www.citeline.com.

About Novotech:

Headquartered in Sydney with a regional hub in Malaysia, Novotech is focused on the Australasian region with 9 offices across the Asia Pacific including India, South Korea and Taiwan. Novotech also has worldwide reach through the company’s network of strategic partners.  Novotech, described by Frost & Sullivan as the best in its industry class for Australia based CROs, brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area.  As the largest independent CRO based in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organizations in the region.  Since 2006, Novotech has been recognized as Australia’s leading CRO by Frost & Sullivan in its Asia Pacific Excellence in Healthcare awards.  More information available at www.novotech-cro.com

For additional information contact:

Sarah Powell, Marketing Director, Citeline, Inc., sarah.powell@citeline.com

For Novotech

Susan Fitzpatrick-Napier USA: +1 650 798 5238 Australia: +1 61 2 90061614

Susan@DMG-Agency.com